Cannabidiol in Anorexia Nervosa: A Double‐Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change

Abstract Objective: Anorexia nervosa (AN) is a severe psychiatric disorder marked by an intense fear of gaining weight and persistent body dissatisfaction, both during periods of underweight and after weight restoration. The endocannabinoid system may offer therapeutic benefits, particularly in reducing anxiety. This randomized controlled trial of cannabidiol (CBD) investigated safety, tolerability, pharmacokinetics, and symptomatic improvement in AN. Method: In a double‐blind design, women with AN or Atypical AN were randomized to receive CBD (n = 16) or placebo (n